within Pharmacolibrary.Drugs.ATC.J;

model J01DH56
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00016583333333333332,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 0.0165,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0107,
    k12             = 17.9,
    k21             = 17.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DH56</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Imipenem, cilastatin and relebactam is a fixed-dose combination antibiotic used for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired or ventilator-associated bacterial pneumonia in adult patients. Imipenem is a carbapenem antibiotic, cilastatin is a renal dehydropeptidase inhibitor that prevents the degradation of imipenem, and relebactam is a beta-lactamase inhibitor that broadens the antibiotic spectrum. The combination is approved and in current clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult subjects following single intravenous dose administration. Based on published population pharmacokinetic analysis.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DH56;
